Locations:
SearchGenomic testing isn’t just for low-risk tumors
Image content: This image is available to view online.
View image online (https://assets.clevelandclinic.org/transform/77674915-1aeb-4ac4-82e3-b6827729fe47/650x450-ASCO-Klein_jpg)
650×450-ASCO Klein
Recently developed biopsy-based genomic tests are typically used to predict the likelihood of adverse pathology in men with very low- and low-risk prostate tumors.
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
In this video, and in a poster presentation at the 2016 American Society of Clinical Oncology annual meeting, Cleveland Clinic Glickman Urological & Kidney Institute Chairman Eric Klein, MD, describes efforts to expand genomic testing to stratify good and bad outcomes in men with intermediate- and high-risk early-stage prostate cancer.
This video originally appeared on VJOncology.com, the Video Journal of Oncology, and is used with permission.
Video content: This video is available to watch online.
View video online (https://www.youtube.com/embed/xPa9HsUV0vo?feature=oembed)
Advertisement
Advertisement
First-of-its-kind research investigates the viability of standard screening to reduce the burden of late-stage cancer diagnoses
Global R&D efforts expanding first-line and relapse therapy options for patients
Study demonstrates ability to reduce patients’ reliance on phlebotomies to stabilize hematocrit levels
A case study on the value of access to novel therapies through clinical trials
Findings highlight an association between obesity and an increased incidence of moderate-severe disease
Cleveland Clinic Cancer Institute takes multi-faceted approach to increasing clinical trial access 23456
Key learnings from DESTINY trials
Overall survival in patients treated since 2008 is nearly 20% higher than in earlier patients